MASON, Ohio--(BUSINESS WIRE)--Mar. 6, 2017--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
management, today announced it has hired Vinayak (Vini) Doraiswamy, PhD
as its Senior Vice President of Clinical, Regulatory, and Scientific
Affairs.
Most recently, Dr. Doraiswamy served as Vice President of Global
Clinical Operations at St. Jude Medical. In his role he oversaw clinical
operations for over 100 clinical trials across the world, and managed a
team of over 300 people. During his time at St. Jude Medical, he led the
integration of several teams into a unified global clinical operations
organization and also helped design and execute one of the largest
pivotal IDE catheter ablation trials in the Afib space. Prior to his
most recent role, he spent a large portion of his career in the Afib
market and served in various leadership capacities in program
management, clinical affairs, strategic planning, and portfolio
management. Prior to joining St. Jude Medical, Dr. Doraiswamy held
several positions of increasing responsibility in marketing, field
clinical engineering, IDE and post market clinical studies at Boston
Scientific.
“We are excited to have Vini join AtriCure,” said Mike Carrel, President
and Chief Executive Officer. “His deep knowledge of the Afib space, and
his vast array of experiences, will be of substantial benefit to the
company. With our intense focus on clinical science, and the importance
of our clinical and scientific initiatives over the next several years,
now is a great time to enhance our leadership with this critical hire.”
“I am thrilled to be joining AtriCure, and am ready to get to work by
helping achieve the company’s mission,” said Dr. Doraiswamy. “There were
many factors that attracted me to the opportunity, but at the forefront
is the company’s scope of initiatives from a clinical and a scientific
perspective. The volume of activity currently underway is impressive,
and many of the trials, including the CONVERGE IDE trial, are
groundbreaking in nature.”
The CONVERGE IDE trial is a landmark prospective, randomized trial
underway in the United States comparing the Convergent approach to
endocardial catheter ablation for patients with persistent or
long-standing persistent Afib. The Convergent approach is a
multi-disciplinary therapy in which a closed-chest epicardial ablation
is performed by a surgeon, and then complemented by an endocardial
catheter ablation performed by an electrophysiologist. The 153 patient
trial currently has 54 patients enrolled at multiple centers. In
addition to the ongoing IDE trial, individual center results have been
published in numerous peer reviewed papers.
“In addition to CONVERGE, there are many other important projects across
the globe that are bringing new products and new evidence that will
serve as the foundation for AtriCure for years to come,” continued Dr.
Doraiswamy. “There are millions of patients worldwide who can benefit
from the therapies we have invested in and will continue to develop in
the coming years. This is an incredible opportunity and I am humbled to
be part of the team.”
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of
Afib and related conditions. Afib affects more than 33 million people
worldwide. Electrophysiologists and cardiothoracic surgeons around the
globe use AtriCure technologies for the treatment of Afib and reduction
of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation
System is the first and only medical device to receive FDA approval for
the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial
Appendage Exclusion System products are the most widely sold LAA
management devices worldwide. For more information, visit AtriCure.com
or follow us on Twitter @AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170306005178/en/
Source: AtriCure, Inc.
AtriCure, Inc.
Media Relations
Valerie Storch-Willhaus,
612-605-3311
Director, Corporate Marketing and Communications
vstorch-willhaus@atricure.com
or
Investor
Relations
Andy Wade, 513-755-4564
Senior Vice President and
Chief Financial Officer
awade@AtriCure.com